BSE: LAURUSLABS - Laurus Labs Limited

Rentabilität für sechs Monate: +22.07%

Aktionsplan Laurus Labs Limited

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs.

weitere details
In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

ISIN INE947Q01028
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.248
Дивиденд ао 0.8
Сайт https://www.lauruslabs.com
Цена ао 558.8
Preisänderung pro Tag: +1.54% (558.8)
Preisänderung pro Woche: -7.39% (612.7)
Preisänderung pro Monat: -1% (573.15)
Preisänderung über 3 Monate: +17.78% (481.75)
Preisänderung über sechs Monate: +22.07% (464.8)
Preisänderung pro Jahr: +36.81% (414.75)
Preisänderung über 3 Jahre: +7.92% (525.75)
Preisänderung über 5 Jahre: +67.2% (339.35)
Preisänderung über 10 Jahre: 0% (567.4)
Preisänderung seit Jahresbeginn: -0.9254% (572.7)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 4.47 4
P/BV 5.44 2
P/E 139.4 1
EV/EBITDA 14.08 7
Gesamt: 4.5

Effizienz

Name Bedeutung Grad
ROA, % 1.91 1
ROE, % 3.91 1
Gesamt: 1.83

Dividenden

Name Bedeutung Grad
Div yield, % 0.3494 0.88
DSI 0.8571 8.57
Gesamt: 3.3

Pflicht

Name Bedeutung Grad
Debt/EBITDA 1.57 7
Gesamt: 6.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 76.63 8
Rentabilität Ebitda, % 188.31 10
Rentabilität EPS, % -15.58 0
Gesamt: 3.6
Weitere Details

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares MSCI India Small-Cap ETF 0.47272 0.4625 0.96163
iShares MSCI Emerging Markets Small-Cap ETF 0.14838 7.67 2.7853
Franklin FTSE India ETF 0.12135 20.52 1.25133
WisdomTree India Earnings Fund 0.11416 5.23 1.65591
Dimensional Emerging Markets Core Equity 2 ETF 0.07105 15.96 3.34087
WisdomTree Emerging Markets SmallCap Dividend Fund 0.04081 1.35 5.00999
Avantis Emerging Markets Equity ETF 0.03524 8.77 3.60513
Avantis Emerging Markets Value ETF 0.03274 14.12 4.22231
Franklin FTSE Asia ex Japan ETF 0.03027 14.43 2.66768
WisdomTree Global ex-U.S. Quality Dividend Growth Fund 0.01699 9.11 2.73928
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.01631 12.46 3.59676
SPDR Portfolio Emerging Markets ETF 0.01552 11.59 3.1879
SPDR Portfolio MSCI Global Stock Market ETF 0.01304 17.99 2.19607
Dimensional World ex U.S. Core Equity 2 ETF 0.01011 13.06 3.62488
Vanguard ESG International Stock ETF 0.01 6.39 3.07501
iShares Core MSCI Total International Stock ETF 0.00853 6.4 3.25258

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Satyanarayana Chava M.Sc., Ph.D. CEO & Whole Time Director 186.44M 1961 (64 Jahr)
Mr. Vantaram Venkata Ravi Kumar Dip in Mgmt., DIS, F.C.M.A. CFO & Whole-Time Director 49.65M 1965 (60 Jahre)
Mr. B. V. R. K. Suryadevara Srinivasa Rao Executive Vice President of Manufacturing & Operations N/A 1968 (57 Jahre)
Mr. Narasimha Rao Chava Executive Vice President of Human Resources N/A 1968 (57 Jahre)
Dr. Lakshmana Rao Venkata Chunduru M.Sc., Ph.D. Head of Quality & Executive Director 33M 1962 (63 Jahr)
Mr. Srinivasa Rao Suryadevara B.Sc, M.Sc. Executive Vice President of Manufacturing N/A 1963 (62 Jahr)
Mr. Chagarlamudi Sita Ramaiah Executive Vice President of Finance N/A 1973 (52 Jahr)
Mr. Dammalapati Venkata Lakshmi Narasimha Rao Executive Vice President of Synthesis N/A 1969 (56 Jahre)
Mr. Krishna Chaitanya Chava Executive VP, Head of Synthesis & Ingredients and Executive Director N/A 1990 (35 Jahre)
Mr. Rajaram Iyer M.B.A. Executive Vice President of Portfolio Management 1974 (51 Jahr)

Adresse: India, Hyderabad, Serene Chambers - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.lauruslabs.com